Flu drug developer BioCryst Pharmaceuticals Inc. priced its 5 million common stock share offering at $9.75 per share. On Thursday after the markets closed the company estimated gross proceeds of $48.8 million. The banks underwriting its offer will have the…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook




Stock – Common stock – BioCryst Pharmaceuticals – Business – Underwriting

Excerpted from:
BioCryst prices stock offering at $9.75 per share